Professional Media briefs

Quadrant HealthCom is purchasing the journal publishing unit of Dowden Health Media from Lebhar-Friedman. The sale effectively moves Dowden's seven journals—including Mayo Clinic Proceedings and The Journal of Family Practice—into Quadrant's lineup.

Elsevier said it is re-launching Embase, its biomedical database of over 20 million indexed records from more than 7,000 active, peer-reviewed journals. Improvements include expanded usability and new retrieval tools, the company said.

Harvard, Johns Hopkins and eight other top medical schools received an inquiry from Sen. Charles Grassley (R-IA) about their ghostwriting policies. “Any attempt to manipulate the scientific literature…is very troubling,” Grassley wrote the schools, according to the New York Times.

Unbound Medicine released Evidence Central, an integrated, evidence-based tool for mobile devices and the web. Cochrane Abstracts and Evidence-Based Medicine Guidelines are designed to deliver answers to problem-based questions while graded and validated EE+ POEMs (Patient-Oriented Evidence that Matters from Essential Evidence Plus) and MEDLINE Journals are offered daily.
You must be a registered member of MMM to post a comment.

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.